Skip to content

Released Nov 7, 2011, after the close

10-Q filed Nov 7, 2011, 38 days after period end · 0001144204-11-061636

Q3 2011 · 10-Q
Revenue$1.13M−64.4% vs Q3 2010+48.2% vs Q2 2011
Net Income-$8.88MN/M vs Q3 2010N/M vs Q2 2011
EPS Diluted-$0.10N/M vs Q3 2010N/M vs Q2 2011
Gross Profit$677,000−68.1%
Operating Income-$8,767,000N/M
Operating Cash Flowderived-$8,147,000N/M
Free Cash Flowderived-$9,132,000N/M
Margins · derived
Gross margin59.8%−6.7 pt vs Q3 2010
Operating margin-774.5%−685.0 pt vs Q3 2010
Net margin-784.0%−706.3 pt vs Q3 2010

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2011Q3 2010
Revenue$1.13M$3.18M
Net Income-$8.88M-$2.47M
EPS Diluted-$0.10$0.03

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR